The Hidden Costs of Delayed APAC Engagement in Global Oncology Trials
Global oncology clinical trials face growing pressure to accelerate timelines, reach diverse patient populations, and generate data that can support regulatory and market access goals across regions.
Moderated by Ian Haydock (Citeline), the session brought together experts from Southern Star Research, Takeda, Expecto Health Science, and the Experimental Drug Development Centre to discuss the hidden costs of delayed APAC engagement in global oncology trials.
The report explores why APAC is often considered too late in global oncology programs, and how delayed regional engagement can create challenges beyond recruitment. It considers the issue from multiple perspectives, including sponsor decision-making, trial design, regulatory expectations, local data requirements, and the operational realities of conducting oncology studies across APAC.
The discussion offers a strategic look at oncology trial planning, APAC oncology clinical trials landscape and the challenges that may only become visible later in development.
To explore the insights shared by Amanda Jubb, Mi-Young Park, Samir Sadekar, and Inderjeet Singh, download the full executive summary here.